Literature DB >> 21619947

Autoimmune disorders affecting both the central and peripheral nervous system.

Christoph Kamm1, Uwe K Zettl.   

Abstract

Various case series of patients with autoimmune demyelinating disease affecting both the central and peripheral nervous system (CNS and PNS), either sequentially or simultaneously, have been reported for decades, but their frequency is considerably lower than that of the "classical" neurological autoimmune diseases affecting only either CNS or PNS, such as multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP) or Guillain-Barré-Syndrome (GBS), and attempts to define or even recognize the former as a clinical entity have remained elusive. Frequently, demyelination started with CNS involvement with subsequent PNS pathology, in some cases with a relapsing-remitting course. Three potential mechanisms for the autoimmune etiology of these conditions can be discussed: (I) They could be caused by a common autoimmunological reactivity against myelin antigens or epitopes present in both the central and peripheral nervous system; (II) They could be due to a higher general susceptibility to autoimmune disease, which in some cases may have been caused or exacerbated by immunomodulatory treatment, e.g. b-interferon; (III) Their co-occurrence might be coincidental. Another example of an autoimmune disease variably involving the central or peripheral nervous system or both is the overlapping and continuous clinical spectrum of Fisher syndrome (FS), as a variant of GBS, and Bickerstaff brainstem encephalitis (BBE). Recent data from larger patient cohorts with demonstration of common autoantibodies, antecedent infections, and results of detailed clinical, neuroimaging and neurophysiological investigations suggest that these three conditions are not separate disorders, but rather form a continuous spectrum with variable central and peripheral nervous system involvement. We herein review clinical and paraclinical data and therapeutic options of these disorders and discuss potential underlying common vs. divergent immunopathogenic mechanisms.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21619947     DOI: 10.1016/j.autrev.2011.05.012

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  18 in total

Review 1.  Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review.

Authors:  Savino Sciascia; Maria Laura Bertolaccini; Dario Roccatello; Munther A Khamashta; Giovanni Sanna
Journal:  J Neurol       Date:  2014-06-21       Impact factor: 4.849

2.  A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band.

Authors:  Diana Ferraro; Diego Franciotta; Roberta Bedin; Claudio Solaro; Eleonora Cocco; Mario Santangelo; Paolo Immovilli; Alberto Gajofatto; Massimiliano Calabrese; Massimiliano Di Filippo; Riccardo Orlandi; Anna Maria Simone; Francesca Vitetta; Elisabetta Capello; Debora Giunti; Alessandra Murialdo; Jessica Frau; Sara Mariotto; Antongiulio Gallina; Claudio Gasperini; Patrizia Sola
Journal:  J Neurol       Date:  2017-04-05       Impact factor: 4.849

3.  Evaluation of locomotor function and microscopic structure of the spinal cord in a mouse model of experimental autoimmune encephalomyelitis following treatment with syngeneic mesenchymal stem cells.

Authors:  Nilesh Kumar Mitra; Umesh Bindal; Wong Eng Hwa; Caroline L L Chua; Chek Ying Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 4.  Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders.

Authors:  Hema Kumari Alajangi; Mandeep Kaur; Akanksha Sharma; Sumedh Rana; Shipali Thakur; Mary Chatterjee; Neha Singla; Pradeep Kumar Jaiswal; Gurpal Singh; Ravi Pratap Barnwal
Journal:  Mol Brain       Date:  2022-06-01       Impact factor: 4.399

Review 5.  Immunoglobulin-mediated neuro-cognitive impairment: new data and a comprehensive review.

Authors:  Assaf Menachem; Joab Chapman; Yael Deri; Chaim G Pick; Aviva Katzav
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

6.  Treatment for experimental autoimmune neuritis with clodronate (Bonefos).

Authors:  Aviva Katzav; Hofit Bina; Ramona Aronovich; Joab Chapman
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

7.  Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.

Authors:  Jérôme J Devaux; Yumako Miura; Yuki Fukami; Takayuki Inoue; Constance Manso; Maya Belghazi; Kenji Sekiguchi; Norito Kokubun; Hiroo Ichikawa; Anna Hiu Yi Wong; Nobuhiro Yuki
Journal:  Neurology       Date:  2016-02-03       Impact factor: 9.910

Review 8.  CNS autoimmunity in children: An unwanted wrinkle in a smooth narrative.

Authors:  Lokesh Saini; Vishal Sondhi
Journal:  Med J Armed Forces India       Date:  2021-03-24

9.  IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome.

Authors:  Shujuan Li; Ming Yu; Haifeng Li; Hongliang Zhang; Yanfang Jiang
Journal:  Mediators Inflamm       Date:  2012-10-02       Impact factor: 4.711

10.  Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis.

Authors:  Christina Elliott; Maren Lindner; Ariel Arthur; Kathryn Brennan; Sven Jarius; John Hussey; Andrew Chan; Anke Stroet; Tomas Olsson; Hugh Willison; Susan C Barnett; Edgar Meinl; Christopher Linington
Journal:  Brain       Date:  2012-05-04       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.